Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐ aspartate aminotransferase score

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study

(2021) Takeshi Hatanaka et al.   INTERNAL MEDICINE

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

(2020) Philip N Newsome et al.   Lancet Gastroenterology & Hepatology

Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison between M and XL probes

(2020) Satoshi Oeda et al.   HEPATOLOGY RESEARCH

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

(2020) Yusuke Sasaki et al.   Scientific Reports

Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination

(2020) Eiichi Ogawa et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study

(2020) Yuya Seko et al.   HEPATOLOGY RESEARCH

Outcomes of Liver Transplantation for Non-alcoholic Steatohepatitis: a European Liver Transplant Registry Study

(2019) Debashis Haldar et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

(2018) Shun Ishibashi et al.   Journal of Clinical Lipidology

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

(2018) Chris Estes et al.   JOURNAL OF HEPATOLOGY

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

(2018) Yoshio Sumida et al.   HEPATOLOGY RESEARCH

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials

(2017) Yuya Seko et al.   JOURNAL OF GASTROENTEROLOGY

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

(2017) Yasushi Honda et al.   Scientific Reports

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

(2016) Shun Ishibashi et al.   ATHEROSCLEROSIS

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

(2016) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease

(2016) Serena Pelusi et al.   PLoS One

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Statin use and non-alcoholic steatohepatitis in at risk individuals

(2015) Paola Dongiovanni et al.   JOURNAL OF HEPATOLOGY

Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials

(2015) Ken Sato et al.   NUTRITION

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

(2013) Jean-Charles Fruchart   Cardiovascular Diabetology

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

(2009) Amy G. Shah et al.   Clinical Gastroenterology and Hepatology